IRF-3 gene polymorphisms are associated with the susceptibility to and the survival in chronic lymphocytic leukemia and could also serve as an auxiliary index

References

• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116:4771–4776.
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:88–96.
   PubMedGoogle Scholar
• Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809–819.
   PubMed Web of Science ®Google Scholar
• Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA. 2010;107:12210–12215.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010;21:vii154–vii164.
   PubMed Web of Science ®Google Scholar
• De Marchis ML, Ballarino M, Salvatori B, et al. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia. 2009;23:856–862.
   PubMed Web of Science ®Google Scholar
• Wang XA, Zhang R, She ZG, et al. Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology. 2014;59:870–885.
   PubMed Web of Science ®Google Scholar
• Savitsky D, Tamura T, Yanai H, et al. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 2010;59:489–510.
   PubMed Web of Science ®Google Scholar
• Lu J, Bian ZY, Zhang R, et al. Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol. 2013;108:326.
   PubMed Web of Science ®Google Scholar
• Tarassishin L, Suh HS, Lee SC. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. J Neuroinflammation. 2011;8:187.
   PubMed Web of Science ®Google Scholar
• Akahoshi M, Nakashima H, Sadanaga A, et al. Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus. Lupus. 2008;17:568–574.
   PubMed Web of Science ®Google Scholar
• Tarassishin L, Loudig O, Bauman A, et al. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia. 2011;59:1911–1922.
   PubMed Web of Science ®Google Scholar
• Martin-Antonio B, Suarez-Lledo M, Arroyes M, et al. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. Bone Marrow Transplant. 2013;48:1205–1211.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Roelens I, Lauwerys BR. Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies. Curr Mol Med.. 2008;8:551–561.
   PubMed Web of Science ®Google Scholar
• Havelange V, Pekarsky Y, Nakamura T, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011;118:2827–2829.
   PubMed Web of Science ®Google Scholar
• World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. TLR signaling. Semin Immunol.. 2007;19:24–32.
   PubMed Web of Science ®Google Scholar
• Tamura T, Yanai H, Savitsky D, et al. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584.
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol.. 2006;6:644–658.
   PubMed Web of Science ®Google Scholar
• Dogusan Z, Garcia M, Flamez D, et al. Double-stranded RNA induces pancreatic beta-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways. Diabetes. 2008;57:1236–1245.
   PubMed Web of Science ®Google Scholar
• Kim TK, Lee JS, Oh SY, et al. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res. 2007;67:11133–11140.
   PubMed Web of Science ®Google Scholar
• Mori M, Yoneyama M, Ito T, et al. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J Biol Chem. 2004;279:9698–9702.
   PubMed Web of Science ®Google Scholar
• Kim TY, Lee KH, Chang S, et al. Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3. J Biol Chem. 2003;278:15272–15278.
   PubMed Web of Science ®Google Scholar
• Zhang CF, Cao BW, Lu ZM, et al. [Relationship between polymorphism of IRF-3 gene codon 427 and esophageal cancer in Anyang population of China]. Beijing Da Xue Xue Bao. 2004;36:345–347.
   PubMedGoogle Scholar
• Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23:25–47.
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 2008;111:5646–5653.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109:290–297.
   PubMed Web of Science ®Google Scholar